 Marsha Anderson
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 20 | 2026 | 94 | 2.710 |
Why?
| | Immunoglobulins, Intravenous | 7 | 2026 | 133 | 0.780 |
Why?
| | Coronary Aneurysm | 3 | 2026 | 17 | 0.450 |
Why?
| | Infliximab | 4 | 2026 | 111 | 0.430 |
Why?
| | Coronary Vessels | 4 | 2026 | 246 | 0.400 |
Why?
| | Immunologic Factors | 2 | 2026 | 259 | 0.330 |
Why?
| | Internship and Residency | 3 | 2023 | 1262 | 0.220 |
Why?
| | Diagnostic Errors | 2 | 2008 | 177 | 0.210 |
Why?
| | Pediatrics | 4 | 2018 | 1121 | 0.210 |
Why?
| | Fever | 3 | 2020 | 313 | 0.210 |
Why?
| | Benzazepines | 1 | 2004 | 35 | 0.210 |
Why?
| | Child, Preschool | 19 | 2025 | 11790 | 0.200 |
Why?
| | Nasopharynx | 3 | 2015 | 73 | 0.190 |
Why?
| | Infant | 16 | 2026 | 10023 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 287 | 0.190 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 245 | 0.190 |
Why?
| | Child | 18 | 2025 | 22600 | 0.160 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 26 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 587 | 0.140 |
Why?
| | Steroids | 1 | 2019 | 159 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 107 | 0.140 |
Why?
| | Neutrophils | 1 | 2004 | 1118 | 0.140 |
Why?
| | Climate Change | 1 | 2021 | 200 | 0.140 |
Why?
| | Respiratory Tract Infections | 2 | 2015 | 395 | 0.130 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 562 | 0.130 |
Why?
| | Faculty, Medical | 3 | 2018 | 301 | 0.120 |
Why?
| | Algorithms | 2 | 2025 | 1844 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 269 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 233 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 438 | 0.110 |
Why?
| | Calcitonin | 1 | 2015 | 27 | 0.110 |
Why?
| | Physician Executives | 2 | 2018 | 30 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 160 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 114 | 0.110 |
Why?
| | Humans | 29 | 2026 | 144667 | 0.100 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 743 | 0.100 |
Why?
| | Particulate Matter | 1 | 2016 | 337 | 0.100 |
Why?
| | Rhinovirus | 2 | 2015 | 60 | 0.100 |
Why?
| | Colorado | 8 | 2015 | 4558 | 0.090 |
Why?
| | Gastroenteritis | 1 | 2013 | 63 | 0.090 |
Why?
| | Accreditation | 2 | 2023 | 101 | 0.090 |
Why?
| | Disease Outbreaks | 2 | 2007 | 423 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 365 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 392 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1360 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 574 | 0.090 |
Why?
| | Male | 19 | 2026 | 72431 | 0.090 |
Why?
| | Coronavirus | 2 | 2015 | 47 | 0.090 |
Why?
| | Program Development | 2 | 2018 | 368 | 0.080 |
Why?
| | Leadership | 2 | 2018 | 400 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Female | 18 | 2026 | 78304 | 0.080 |
Why?
| | Retrospective Studies | 9 | 2026 | 17149 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1044 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 402 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2013 | 528 | 0.070 |
Why?
| | Enterovirus Infections | 2 | 2008 | 173 | 0.070 |
Why?
| | Picornaviridae Infections | 1 | 2008 | 53 | 0.070 |
Why?
| | Mentors | 1 | 2010 | 214 | 0.070 |
Why?
| | Echocardiography | 2 | 2026 | 644 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 304 | 0.070 |
Why?
| | Enterovirus A, Human | 1 | 2007 | 13 | 0.070 |
Why?
| | Curriculum | 2 | 2021 | 1063 | 0.060 |
Why?
| | Logistic Models | 2 | 2018 | 2114 | 0.060 |
Why?
| | HIV Infections | 1 | 2002 | 3148 | 0.060 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2007 | 78 | 0.060 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1501 | 0.060 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 557 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 218 | 0.060 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2008 | 288 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1505 | 0.060 |
Why?
| | Medical Records | 2 | 2018 | 191 | 0.060 |
Why?
| | Medical Audit | 1 | 2005 | 77 | 0.050 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 205 | 0.050 |
Why?
| | CD11b Antigen | 1 | 2004 | 60 | 0.050 |
Why?
| | Clinical Competence | 2 | 2023 | 1237 | 0.050 |
Why?
| | Infectious Disease Medicine | 1 | 2023 | 12 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 249 | 0.050 |
Why?
| | Superoxides | 1 | 2004 | 199 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 265 | 0.050 |
Why?
| | Coronavirus Infections | 1 | 2006 | 381 | 0.040 |
Why?
| | United States | 4 | 2025 | 16018 | 0.040 |
Why?
| | Ultrasonography | 1 | 2005 | 776 | 0.040 |
Why?
| | Knowledge | 1 | 2021 | 57 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1047 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 35 | 0.040 |
Why?
| | Schools, Medical | 2 | 2014 | 158 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2020 | 3603 | 0.040 |
Why?
| | Health Resources | 1 | 2021 | 130 | 0.040 |
Why?
| | Time Factors | 2 | 2016 | 7140 | 0.040 |
Why?
| | Risk Factors | 3 | 2018 | 10796 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2019 | 6399 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2026 | 11735 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 319 | 0.030 |
Why?
| | Education, Medical | 1 | 2021 | 273 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 779 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 851 | 0.030 |
Why?
| | Learning | 1 | 2021 | 448 | 0.030 |
Why?
| | Biomarkers | 2 | 2020 | 4261 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 96 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 650 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2019 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1995 | 0.030 |
Why?
| | Canada | 1 | 2016 | 432 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 142 | 0.030 |
Why?
| | Systole | 1 | 2015 | 177 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 401 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3729 | 0.030 |
Why?
| | Adenoviridae | 1 | 2015 | 199 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2117 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 1928 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 605 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 944 | 0.030 |
Why?
| | Adolescent | 3 | 2019 | 22409 | 0.030 |
Why?
| | Exanthema | 1 | 2013 | 84 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 517 | 0.020 |
Why?
| | Physicians | 1 | 2021 | 949 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2013 | 147 | 0.020 |
Why?
| | Incidence | 2 | 2012 | 2892 | 0.020 |
Why?
| | Cohort Studies | 2 | 2018 | 5957 | 0.020 |
Why?
| | Needs Assessment | 1 | 2014 | 401 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 85 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 99 | 0.020 |
Why?
| | Prevalence | 2 | 2008 | 2839 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 151 | 0.020 |
Why?
| | Societies, Medical | 1 | 2014 | 890 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2015 | 915 | 0.020 |
Why?
| | Enterovirus | 1 | 2008 | 83 | 0.020 |
Why?
| | Meningitis, Aseptic | 1 | 2007 | 13 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2007 | 31 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2922 | 0.020 |
Why?
| | Peer Group | 1 | 2010 | 256 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 88 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2870 | 0.020 |
Why?
| | Paralysis | 1 | 2007 | 68 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7994 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2007 | 119 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 852 | 0.020 |
Why?
| | Patient Admission | 1 | 2008 | 220 | 0.020 |
Why?
| | Respiratory System | 1 | 2007 | 151 | 0.010 |
Why?
| | Prognosis | 1 | 2015 | 4312 | 0.010 |
Why?
| | Clinical Clerkship | 1 | 2007 | 109 | 0.010 |
Why?
| | Encephalitis | 1 | 2007 | 142 | 0.010 |
Why?
| | Program Evaluation | 1 | 2010 | 941 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 1029 | 0.010 |
Why?
| | Adult | 2 | 2014 | 40489 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2007 | 207 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 828 | 0.010 |
Why?
| | RNA, Viral | 1 | 2006 | 689 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2002 | 331 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2002 | 516 | 0.010 |
Why?
| | Reference Values | 1 | 2002 | 794 | 0.010 |
Why?
| | Odds Ratio | 1 | 2002 | 1076 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2002 | 1301 | 0.010 |
Why?
| | Urban Population | 1 | 2002 | 493 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 35971 | 0.010 |
Why?
|
|
Anderson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|